Oncogenic and tumor-suppressive microRNAs in prostate cancer.
Curr Opin Endocr Metab Res
; 10: 50-59, 2020 Feb.
Article
em En
| MEDLINE
| ID: mdl-33043165
ABSTRACT
MicroRNAs are known to be dysregulated in prostate cancer. These small noncoding RNAs can function as biomarkers and are involved in the biology of prostate cancer. The canonical mechanism for microRNAs is post-transcription regulation of gene expression via binding to the 3' untranslated region of mRNAs, resulting in RNA degradation and/or translational repression. Thus, oncogenic microRNAs, also known as oncomiRs, often have high expression in prostate cancer and target the mRNAs of tumor suppressors. Conversely, tumor-suppressive microRNAs have reduced expression in cancer and typically target oncogenes. Some microRNAs function outside the classical mechanism and serve to stabilize their mRNA targets. Herein, we review contemporary studies that demonstrate oncogenic and tumor-suppressive activity of microRNAs in prostate cancer.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Curr Opin Endocr Metab Res
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos